Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joan Maurel

Showing results (71-80 of 116) with videos related to

Pageof 12
Sort By:
Medicina Clinica|February 13, 2009
[Prediction of prognosis of patients with pancreatic adenocarcinoma with curative intent resection by means of histologic grade and pathologic N stage]Antonio Soriano-Izquierdo, Ana C Adet, Rosa Gallego, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2007
Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors TrialEduardo Díaz-Rubio, Jose Tabernero, Auxiliadora Gómez-España, et al.
Molecular Cancer Therapeutics|July 2, 2014
Pharmacogenetic predictors of outcome in patients with stage II and III colon cancer treated with oxaliplatin and fluoropyrimidine-based adjuvant chemotherapyAna Custodio, Juan Moreno-Rubio, Jorge Aparicio, et al.
International Journal of Cancer|July 27, 2012
Gene-expression signature of tumor recurrence in patients with stage II and III colon cancer treated with 5'fluoruracil-based adjuvant chemotherapyMaría Dolores Giráldez, Juan José Lozano, Míriam Cuatrecasas, et al.
Clinical and Experimental Medicine|November 25, 2025
Prognostic value of whole lymph node molecular analysis in colorectal cancer: a prospective multicenter studyQing Liu, Sandra Lopez-Prades, Karmele Saez de Gordoa, et al.
European Journal of Cancer (Oxford, England : 1990)|July 19, 2016
Phase II randomised trial of autologous tumour lysate dendritic cell plus best supportive care compared with best supportive care in pre-treated advanced colorectal cancer patientsMiguel Caballero-Baños, Daniel Benitez-Ribas, Jaime Tabera, et al.
Cancers|December 11, 2022
Mutational Status of <i>SMAD4</i> and <i>FBXW7</i> Affects Clinical Outcome in <i>TP53</i>-Mutated Metastatic Colorectal CancerSara Lahoz, Adela Rodríguez, Laia Fernández, et al.
Gut|August 2, 2019
ZEB1 promotes inflammation and progression towards inflammation-driven carcinoma through repression of the DNA repair glycosylase MPG in epithelial cellsOriol de Barrios, Lidia Sanchez-Moral, Marlies Cortés, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 27, 2022
Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01)Jorge Aparicio, Anna C Virgili Manrique, Jaume Capdevila, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2025
An Exosome-Based Liquid Biopsy Predicts Depth of Response and Survival Outcomes to Cetuximab and Panitumumab in Metastatic Colorectal Cancer: The EXONERATE StudyCaiming Xu, Alessandro Mannucci, Francis Esposito, et al.
Pageof 12

Showing results (71-80 of 116) with videos related to

Sort By:
Pageof 12
Medicina Clinica|February 13, 2009
[Prediction of prognosis of patients with pancreatic adenocarcinoma with curative intent resection by means of histologic grade and pathologic N stage]Antonio Soriano-Izquierdo, Ana C Adet, Rosa Gallego, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2007
Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors TrialEduardo Díaz-Rubio, Jose Tabernero, Auxiliadora Gómez-España, et al.
Molecular Cancer Therapeutics|July 2, 2014
Pharmacogenetic predictors of outcome in patients with stage II and III colon cancer treated with oxaliplatin and fluoropyrimidine-based adjuvant chemotherapyAna Custodio, Juan Moreno-Rubio, Jorge Aparicio, et al.
International Journal of Cancer|July 27, 2012
Gene-expression signature of tumor recurrence in patients with stage II and III colon cancer treated with 5'fluoruracil-based adjuvant chemotherapyMaría Dolores Giráldez, Juan José Lozano, Míriam Cuatrecasas, et al.
Clinical and Experimental Medicine|November 25, 2025
Prognostic value of whole lymph node molecular analysis in colorectal cancer: a prospective multicenter studyQing Liu, Sandra Lopez-Prades, Karmele Saez de Gordoa, et al.
European Journal of Cancer (Oxford, England : 1990)|July 19, 2016
Phase II randomised trial of autologous tumour lysate dendritic cell plus best supportive care compared with best supportive care in pre-treated advanced colorectal cancer patientsMiguel Caballero-Baños, Daniel Benitez-Ribas, Jaime Tabera, et al.
Cancers|December 11, 2022
Mutational Status of <i>SMAD4</i> and <i>FBXW7</i> Affects Clinical Outcome in <i>TP53</i>-Mutated Metastatic Colorectal CancerSara Lahoz, Adela Rodríguez, Laia Fernández, et al.
Gut|August 2, 2019
ZEB1 promotes inflammation and progression towards inflammation-driven carcinoma through repression of the DNA repair glycosylase MPG in epithelial cellsOriol de Barrios, Lidia Sanchez-Moral, Marlies Cortés, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 27, 2022
Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01)Jorge Aparicio, Anna C Virgili Manrique, Jaume Capdevila, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2025
An Exosome-Based Liquid Biopsy Predicts Depth of Response and Survival Outcomes to Cetuximab and Panitumumab in Metastatic Colorectal Cancer: The EXONERATE StudyCaiming Xu, Alessandro Mannucci, Francis Esposito, et al.
Pageof 12